Subject characteristics
| Patients (n=45) | Controls (n=21) | p Value | |
|---|---|---|---|
| Values are means (SD). | |||
| ACEI, angiotensin converting enzyme inhibitor; AIIA, angiotensin II inhibitor; FEV1, forced expiratory volume in one second; FVC, forced ventilatory capacity; LVEDD, left ventricular end diastolic dimension from M mode echocardiography; LVEF, ejection fraction (%); PV̇o2, peak oxygen consumption; RER, respiratory exchange ratio (carbon dioxide production to oxygen consumption (V̇co2/V̇o2)); VE, ventilatory response. | |||
| Age (years) | 69 (9.6) | 66 (8.1) | 0.18 |
| Height (cm) | 171 (6.9) | 175 (6.9) | 0.06 |
| Weight (kg) | 78.6 (13.5) | 79.7 (10.5) | 0.74 |
| FEV1 (% expected) | 90.0 (17.4) | 116.0 (23.4) | <0.0001 |
| FVC (% expected) | 80.0 (22.9) | 95.0 (22.6) | 0.0001 |
| Sex (male:female) | 41:4 | 18:3 | |
| LVEDD (cm) | 6.5 (0.7) | 5.0 (0.6) | <0.0001 |
| LVEF (%) | 33.6 (5.4) | 61.0 (9.9) | <0.0001 |
| Drugs | |||
| Furosemide (mean daily dose) | 83.4 (53.4) | ||
| β Blockers (n) | 15 | ||
| ACEI/AIIA (n) | 44 | ||
| Spironolactone (n) | 21 | ||
| New York Heart Association (functional class n) | |||
| II | 27 | ||
| III | 18 | ||
| V̇o2 (ml/kg/min) | 19.7 (4.5) | 37.9 (8.6) | <0.0001 |
| Exercise time (s) | 420 (132) | 817 (208) | <0.0001 |
| Anaerobic threshold (ml/kg/min) | 14.3 (3.7) | 28.4 (8.4) | <0.0001 |
| RER | 1.05 (0.06) | 1.05 (0.07) | 0.92 |
| Borg/V̇E slope | 0.176 (0.04) | 0.123 (0.07) | 0.001 |
| V̇E/V̇co2 slope | 40.0 (6.5) | 26.0 (1.6) | <0.0001 |